The ATTAIN-2 trial was a 72-week, phase 3, double-blind, randomized, multicenter, placebo-controlled trial at 136 sites in ten countries.[1] Adult patients with obesity or overweight (BMI ≥ 27 kg/m²) and type 2 diabetes (HbA1c 7–10%, i.e. 53–86 mmol/mol) were included.[1] Participants were randomly assigned in a 1:1:1:2 ratio to orforgliprone 6 mg, 12 mg, 36 mg, or placebo administered once daily as an adjunct to lifestyle modification.[1] The primary endpoint was the percent reduction in body weight from baseline to week 72 as estimated by the treatment regimen.[1] At 6 mg, weight loss averaged -5.1% (95% CI -6.0 to -4.2), with an estimated difference from placebo of -2.7% (95% CI -3.7%).[1] Orforglipron demonstrated a statistically significant reduction in body weight compared to placebo.[1] The safety profile of the drug was similar to that of other GLP-1 receptor agonists.[1]